Iveda Solutions, Inc. current report, 28 September 2023

Business Context and Reporting Period

This Form 8-K was filed by Iveda Solutions, Inc. (Nasdaq: IVDA) on September 28, 2023. The report addresses a regulatory notice received from The Nasdaq Stock Market regarding the company's compliance with continued listing standards.

Key Financial Metrics

The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the status of the company's stock listing.

Material Changes

The material event reported is the receipt of a written notice from Nasdaq stating that the company's common stock failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive trading days. This deficiency is based on Nasdaq Listing Rule 5550(a)(2) and Rule 5810(c)(3)(A).

Outlook, Risks, and Management Commentary

  • Compliance Period: The company has been granted an initial 180-calendar-day compliance period to regain compliance, ending on March 26, 2024.
  • Requirements to Cure: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive trading days prior to the deadline.
  • Future Options: If the company fails to comply by the initial deadline, it may be eligible for an additional 180-day period if it meets other listing standards (excluding bid price) and notifies Nasdaq of its intent to cure.
  • Risks: Failure to regain compliance or qualify for an extension could result in delisting. The company explicitly states there is no assurance it will be able to regain compliance or receive further extensions.
  • Current Status: The notice has no immediate effect, and the stock will continue to trade on the Nasdaq Capital Market under the symbol "IVDA."

Investor Verification Checklist

  • Verify the current closing bid price of IVDA common stock to assess proximity to the $1.00 threshold.
  • Monitor company announcements regarding potential reverse stock splits or other corporate actions intended to address the bid price deficiency.
  • Review the company's financial health to determine if it meets the market value of publicly held shares requirement necessary for a potential second compliance period.
  • Track the timeline for the March 26, 2024, deadline for the initial compliance period.